Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment

Abassi, 2012, Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment, British Journal of Pharmacology, 165, 1424, 10.1111/j.1476-5381.2011.01623.x

Bers, 2002, Cardiac excitation-contraction coupling, Nature, 415, 198, 10.1038/415198a

Bloomfield, 2015, Incorporating exposure-response modeling into the assessment of QTc interval: A potential alternative to the thorough QT study, Clinical Pharmacology & Therapeutics, 97, 444, 10.1002/cpt.92

Cavero, 2005, ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: A critical analysis, Expert Opinion on Drug Safety, 4, 509, 10.1517/14740338.4.3.509

Chaitman, 2004, Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina, Journal of the American College of Cardiology, 43, 1375, 10.1016/j.jacc.2003.11.045

Chen, 2005, QT prolongation and proarrhythmia by moxifloxacin: Concordance of preclinical models in relation to clinical outcome, British Journal of Pharmacology, 146, 792, 10.1038/sj.bjp.0706389

2008

Dennis, 2007, hERG channel trafficking: Novel targets in drug-induced long QT syndrome, Biochemical Society Transactions, 35, 1060, 10.1042/BST0351060

Fermini, 2016, A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm, Journal of Biomolecular Screening, 21, 1, 10.1177/1087057115594589

Gintant, 2016, Evolution of strategies to improve preclinical cardiac safety testing, Nature Reviews Drug Discovery, 10.1038/nrd.2015.34

Gualdani, 2015, Inhibition of hERG potassium channel by the antiarrhythmic agent mexiletine and its metabolite m-hydroxymexiletine, Pharmacology Research & Perspectives, 3, 10.1002/prp2.160

Guo, 2011, Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes, Toxicological Sciences, 123, 281, 10.1093/toxsci/kfr158

Guo, 2013, Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model, Toxicological Sciences, 136, 581, 10.1093/toxsci/kft205

Halbach, 2003, Estimation of action potential changes from field potential recordings in multicellular mouse cardiac myocyte cultures, Cellular Physiology and Biochemistry, 13, 271, 10.1159/000074542

Hanton, 2007, Preclinical cardiac safety assessment of drugs, Drugs in R&D, 8, 213, 10.2165/00126839-200708040-00002

Harris, 2013, Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays, Toxicological Sciences, 134, 412, 10.1093/toxsci/kft113

Hoffmann, 2006, Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends, Journal of Pharmacological and Toxicological Methods, 53, 87, 10.1016/j.vascn.2005.07.003

Kallergis, 2012, Mechanisms, risk factors, and management of acquired long QT syndrome: A comprehensive review, ScientificWorld Journal, 2012, 212178, 10.1100/2012/212178

Kannankeril, 2010, Drug-induced long QT syndrome, Pharmacological Reviews, 62, 760, 10.1124/pr.110.003723

Katz, 2000, Regulation of cardiac contraction and relaxation, Circulation, 102, IV69

Kovacs, 2004, Mechanism of blebbistatin inhibition of myosin II, The Journal of Biological Chemistry, 279, 35557, 10.1074/jbc.M405319200

Lacerda, 2008, Alfuzosin delays cardiac repolarization by a novel mechanism, Journal of Pharmacology and Experimental Therapeutics, 324, 427, 10.1124/jpet.107.128405

Lamore, 2013, Cellular impedance assays for predictive preclinical drug screening of kinase inhibitor cardiovascular toxicity, Toxicological Sciences, 135, 402, 10.1093/toxsci/kft167

Limame, 2012, Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays, PloS One, 7, 10.1371/journal.pone.0046536

Mirams, 2014, Prediction of thorough QT study results using action potential simulations based on ion channel screens, Journal of Pharmacological and Toxicological Methods, 70, 246, 10.1016/j.vascn.2014.07.002

Paul, 2002, Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine, British Journal of Pharmacology, 136, 717, 10.1038/sj.bjp.0704784

Peters, 2012, Evaluation of cellular impedance measures of cardiomyocyte cultures for drug screening applications, Assay and Drug Development Technologies, 10, 525, 10.1089/adt.2011.442

Redfern, 2003, Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development, Cardiovascular Research, 58, 32, 10.1016/S0008-6363(02)00846-5

Remme, 2010, Sodium channel (dys)function and cardiac arrhythmias, Cardiovascular Therapeutics, 28, 287, 10.1111/j.1755-5922.2010.00210.x

Sager, 2014, Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium, American Heart Journal, 167, 292, 10.1016/j.ahj.2013.11.004

Schram, 2004, Ranolazine: Ion-channel-blocking actions and in vivo electrophysiological effects, British Journal of Pharmacology, 142, 1300, 10.1038/sj.bjp.0705879

Schweikart, 2013, The effects of jaspamide on human cardiomyocyte function and cardiac ion channel activity, Toxicology In Vitro, 27, 745, 10.1016/j.tiv.2012.12.005

Scott, 2014, An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility, Toxicological Sciences, 142, 331, 10.1093/toxsci/kfu186

Tamargo, 2004, Pharmacology of cardiac potassium channels, Cardiovascular Research, 62, 9, 10.1016/j.cardiores.2003.12.026

Towart, 2009, Blockade of the I(Ks) potassium channel: An overlooked cardiovascular liability in drug safety screening?, Journal of Pharmacological and Toxicological Methods, 60, 1, 10.1016/j.vascn.2009.04.197

Tzeis, 2012, Antiarrhythmic properties of ranolazine–from bench to bedside, Expert Opinion on Investigational Drugs, 21, 1733, 10.1517/13543784.2012.716826

Veerman, 2013, Slow delayed rectifier potassium current blockade contributes importantly to drug-induced long QT syndrome, Circulation. Arrhythmia and Electrophysiology, 6, 1002, 10.1161/CIRCEP.113.000239

Wallis, 2010, Integrated risk assessment and predictive value to humans of non-clinical repolarization assays, British Journal of Pharmacology, 159, 115, 10.1111/j.1476-5381.2009.00395.x

Xi, 2011, Functional cardiotoxicity profiling and screening using the xCELLigence RTCA Cardio System, Journal of Laboratory Automation, 16, 415, 10.1016/j.jala.2011.09.002